ISG15 is a ubiquitin-like protein (ubl) that is induced by interferon (IFN) and microbial challenge. Ubls are covalently conjugated to cellular proteins, and may intersect the ubiquitinproteasome system via common substrates or reciprocal regulation. To investigate the relationship between ISG15 conjugation and proteasome function, we treated IFN-induced cells with proteasome inhibitors. Surprisingly, inhibition of proteasomal, but not lysosomal, proteases dramatically enhanced the level of ISG15 conjugates. The stimulation of ISG15 conjugates occurred rapidly in the absence of protein synthesis, and was most dramatic in the cytoskeletal protein fraction. Inhibition of ISG15 conjugation by ATP depletion abrogated the proteasome inhibitor-dependent increase in ISG15 conjugates, suggesting that the effect was mediated by de novo conjugation, rather than protection from proteasomal degradation or inhibition of ISG15 deconjugating activity. The increase in ISG15 conjugates did not occur through a stabilization of the ISG15 E1 enzyme, UBE1L. Furthermore, simultaneous modification of proteins by both ISG15 and ubiquitin did not account for the proteasome inhibitor-dependent increase in ISG15
ISG15 and proteasome function

INTRODUCTION
Ubiquitin, (ub) 1 is the most highly conserved protein among eucaryotes, and functions to posttranslationally modify cellular proteins by covalent conjugation. Ub conjugation is carried out by the concerted activities of E1 (ub activation), E2 (ub conjugation), and E3 (ub ligase)
enzymes in an ATP-dependent process (1) . Sequential transfer of ub-thiolester intermediates between ubiquitin conjugating enzymes results in isopeptide bond formation between the ε-amino group of a substrate lysine residue and the carboxy terminal glycine of ub. The conjugated ub substrate can be targeted for further ubiquitylation in which poly-ubiquitin chains linked through lysine 48 are formed. Importantly, ubiquitylation is reversible, as ub can be removed from conjugates through the action of deconjugating enzymes (DUBs) (2) . DUBs share highly conserved catalytic domains, but exhibit great sequence diversity outside of these regions; the heterogeneity of these noncatalytic domains is thought to reflect substrate-specific activity.
Thus, ubiquitin conjugation is a dynamic balance between conjugation and deconjugation. In the best characterized outcome of ubiquitylation, proteins conjugated to poly-ub chains of four or greater are targeted for degradation in the 26S proteasome (3) . The proteasome is composed of two 19S 'cap' complexes that bind, deubiquitylate, and unfold substrates to facilitate entry into the barrel-shaped 20S proteolytic core. Identification of the protease activities of the proteasome as chymotrypsin-like, trypsin-like, and caspase-like permitted the development of peptide inhibitors of proteasome function. Studies using cell permeable proteasome inhibitors revealed that the ub-proteasome pathway is responsible for 80-90% of protein turnover in cells, and is essential for the regulation of virtually all cellular processes (4). (5) . Ubls are translated with carboxyl-terminal extensions that are processed to expose residues that function in conjugation; this conjugation sequence is comprised of invariant LRGG carboxyl-terminal residues in orthologues of ISG15, Nedd8 and ub (5) . Like ub, ubls form covalent conjugates with cellular proteins that can be reversed by DUB-like enzymes. However, ubl conjugates are not typically targeted for degradation in the proteasome; rather, conjugation to the ubls studied to date modulates the subcellular location, protein interaction, and biochemical activity of substrate proteins (6) . Recent reports have demonstrated reciprocal regulation by ub and ubl conjugation pathways. For example, the ubl SUMO competes with ub for conjugation to lysine residues on IκB resulting in a stabilizing effect of SUMO conjugation (7) . In two other examples of an intersection between ub and ubl pathways, the ubl NEDD8 and its conjugates are degraded in the proteasome via the adaptor protein, NUB1, and SUMO modification of PML, itself a ub E3 enzyme, recruits the 19S proteasome subunit to nuclear bodies (8, 9) . Protein modification by ub and ubls is thus emerging as a complex network of posttranslational regulation with the capacity to rapidly modulate protein function.
ISG15 was among the first interferon stimulated genes (ISG) to be cloned, and is induced independently of IFN, as one of the earliest and strongest responses to microbial challenge (10) (11) (12) . Sequence analysis revealed that ISG15 is a ubl comprised of tandem ub domains (13) . Like other ubls, ISG15 is translated as a 17kD precursor, and the C-terminal octapeptide extension is rapidly processed by a 100kD protease to expose the ISG15 conjugation domain (14, 15) . Free ISG15 is induced rapidly following IFN treatment, and high molecular weight ISG15 conjugates appear following a lag of 12-24h (16) . The ISG15 E1 enzyme, UBE1L, has recently been identified; induction of this enzyme by IFN requires protein synthesis that may account for the lag in conjugate formation (17) . A candidate ISG15 E2 enzyme, 1-8U, has been identified based on its homology to other E2 enzymes, and is a member of a family of interferon-induced genes that are also directly induced by virus and dsRNA (18, 19) . An ISG15 E3 enzyme has not been identified. We and others have recently cloned a DUB, UBP43, that is coordinately induced with ISG15 in response to IFN, dsRNA and LPS, and functions to specifically deconjugate ISG15 from target proteins (20) (21) (22) . ISG15 conjugates are dramatically increased in cells from UBP43-/-mice indicating that ISG15 conjugation is a dynamic process, and that UBP43 serves a critical function in regulating the cellular conjugate pool.
In contrast to the regulation of ISG15 expression and conjugation, little is known about the identity of specific ISG15 conjugates or the functional role of ISG15 conjugation. ISG15
conjugates were reported to localize to intermediate filaments; however, the relationship of this localization to ISG15 function is unclear (23) . Very recently, the protease inhibitor, serpin 2a, was identified as the first ISG15 conjugate; how ISG15 conjugation may modulate the properties of this protein remains to be determined (24) . In light of the interactions reported between ub and other ubls, we investigated the potential role of proteasome function in ISG15 conjugation.
Surprisingly, proteasome inhibitors dramatically increased the level of ISG15 conjugates in IFNtreated cells. This activity did not reflect an increase in ISG15 expression or the stabilization of ISG15 conjugates from proteasome degradation; rather, the increase in ISG15 conjugates was mediated through de novo conjugation. In addition, the proteasome inhibitor-dependent increase in ISG15 conjugates did not occur through the modulation of UBE1L or UBP43. These findings provide the first evidence of a link between ISG15 conjugation and proteasome function, and support a model in which proteins destined for ISG15 conjugation are regulated in a proteasomedependent manner. 
MATERIALS AND METHODS
Reagents. IFN-α2b was obtained from Schering and was used at 1000U/ml. Proteasome inhibitors were from Calbiochem, and used at the following concentrations: MG132 (Z-Leu-LeuLeu-CHO), 20 µM; proteasome inhibitor I (PSI, Z-Ile-Glu(OtBu)-Ala-Leu-CHO), 50 µM;
proteasome inhibitor II (PSII, Z-Leu-Leu-Phe-CHO), 20 µM; alln (N-Acetyl-Leu-Leu-Nle-CHO), 50 µM, and lactacystin, 20 µM. Protease inhibitors, APMSF [(4-Amidino-phenyl)
leupeptin (Ac-Leu-Leu-argininal), and the protease inhibitor cocktail were from Roche. 2-deoxy-D-glucose, 2,4-dinitrophenol, NEM (N-ethylmaleimide), and detergents (digitonin, sodium dodecyl sulfate (SDS), Triton-X 100, Tween 40 and deoxycholate) were from Sigma.
Monoclonal antibody to ISG15 (used at 1 µg/ml) was a kind gift from Ernest Borden (Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, Ohio). The polyclonal rabbit antiubiquitin antibody (used at 2 µg/ml) was generously provided by Arthur L. Haas (Medical College of Wisconsin, Milwaukee, Wisconsin). Rabbit anti-actin polyclonal antibody (used at 1:500 dilution) was from Sigma, and the rabbit polyclonal UBE1L antibody (used at 1 µg/ml) was kindly provided by Ethan Dmitrovsky (Dartmouth Medical School, Hanover, NH). The protein molecular mass marker set was from Invitrogen.
Cell culture and transfection. 2fTGH cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 100 µg/ml penicillin/streptomycin at 37 0 C in a humidified incubator of 5% CO 2 (all cell culture reagents were from Invitrogen). Western blot analysis. Cells were treated as described in figure legends, and total cell lysates were prepared using RIPA (radioimmunoprecipitation assay) buffer (150 mM sodium chloride, Differential detergent fractionation. Cytosolic/membrane, cytoskeleton-associated/nuclear, and cytoskeletal protein fractions were prepared as previously described (25) . Briefly, 2fTGH 1X sample buffer, and were boiled for 5 minutes prior to loading on a 10% SDS PAGE gel.
RESULTS
ISG15 conjugates are increased following treatment with proteasome inhibitor.
Posttranslational modification by ubls including SUMO and NEDD8 can intersect the ubiquitin pathway resulting in agonistic or antagonistic effects on the activity of conjugating enzymes or substrate half-life (7, 26, 27 conjugates.
MG132 is a peptide aldehyde inhibitor of chymotrypsin-like proteasomal proteases with nonspecific activity against calpains and certain lysosomal cysteine proteases (30, 31) . To demonstrate that the proteasome was the MG132 target that mediated the increase in ISG15
conjugates, IFN-induced cells were treated with distinct proteasome inhibitors, including the highly proteasome-specific inhibitor, lactacystin, and inhibitors of lysosomal and cellular proteases. All inhibitors employed were cell permeable, thus access to intracellular targets was contained both free ISG15, and an MG132-stimulated conjugate population ( Figure 3A) . To compare the distribution of ub conjugates following MG132 treatment with that observed for ISG15, the blot in figure 3A was reacted with anti-ub antibody. The monoclonal ISG15 antibody reacts specifically with free ISG15 and ISG15 conjugates; however, the polyclonal ub antibody exhibits cross-reactivity primarily to free ISG15 and, to a lesser degree, with ISG15 conjugates (13, 34) . Thus, free ISG15 is detected by ub antibody in IFN treated cells ( Figure 3B , and
. A minor population of ub conjugates that loosely associated with the cytoskeleton was detected; however, similar to ISG15, the most dramatic MG132-stimulated increase in ub conjugates was observed in a population that is tightly associated with the cytoskeletal fraction.
MG132 treatment also increased ub conjugates in the cytosolic and membrane fraction. These results suggest that cytoskeleton is an important site for proteasome function and ISG15
conjugation. 
The proteasome inhibitor-dependent increase in ISG15 conjugates requires de novo conjugation.
The steady state level of ISG15 conjugates in IFN-treated cells reflects a dynamic balance between conjugating and deconjugating activities (17, 22) . In addition, the observation that proteasome inhibitors enhance ISG15 conjugates suggests that the turnover of ISG15 substrates, prior to or following ISG15 conjugation, may impact the conjugate population. Thus, three possible mechanisms may account for the increase in ISG15 conjugates upon proteasome inhibition: 1) the stabilization of ISG15 conjugates or substrates by protection from proteasome degradation, 2) an increase in de novo ISG15 conjugation activity, and 3) an inhibition of ISG15 deconjugating activity by ubp43. Conjugation of ub and ubls is ATP-dependent, and ATP depletion is an established strategy to inhibit de novo conjugation (37) . To address the role of de novo ISG15 conjugation as a mechanism for the proteasome inhibitor-dependent increase in ISG15 conjugates, IFN-induced 2fTGH cells were treated with MG132 in the presence or absence of the ATP depleting agents, 2-deoxyglucose and 2,4-dinitrophenol. 2-deoxyglucose depletes ATP through the hexokinase shunt resulting in the production of 6-phospho derivatives that cannot be further metabolized, while DNP acts to uncouple the electron transport chain. conjugates by proteasome inhibitors.
NEM antagonizes the stimulation of ISG15 conjugates by proteasome inhibitor.
Ub and ubl deconjugating activity is not ATP dependent; therefore, the finding that ATP depletion abrogated the proteasome inhibitor-dependent increase in ISG15 conjugates suggested Importantly, we cannot distinguish between the effect of NEM on ub-DUBs that act upstream of the proteasome to remove ub from the poly-ubiquitinated substrates, and its effect on ub-DUBs that act downstream of the proteasome to recycle ub from the poly-ub chain. Blocking the activity of upstream ub-DUBs would directly prevent deconjugation leading to increased degradation; whereas, inhibition of downstream ub-DUBs would accumulate poly-ub chains that, in turn, inhibit proteasome activity and mimick the effect of proteasome inhibitors (39) . Indeed, the effect of NEM on ISG15 conjugates may be due to proteasome inhibition by accumulated ub chains. To determine if UBP43 inhibition contributed to the MG132-dependent increase in ISG15
conjugates, IFN-induced cells were first treated with NEM for 20 minutes; NEM was then removed and MG132 was added for 6h. This treatment regimen did not result in toxic effects or cell death (40) . Surprisingly, NEM antagonized the increase in ISG15 conjugates by MG132 in a dose-dependent manner, with a 4-fold reduction in conjugates observed at 50 µM NEM ( figure   6A, compare lanes 3 and 11) . The opposing effects of NEM and MG132 suggested that these agents stimulate ISG15 conjugates by distinct mechanisms. In contrast to ISG15, NEM pretreatment resulted in no significant change in MG132 stabilized ub conjugates. This finding is consistent with the idea that the effect of NEM on ub conjugates was mediated primarily through the inhibition of proteasome activity, and thus was not augmented by MG132 treatment. ( Figure   6B , lanes 3, 5, 7, 9, 11). However, the opposing effects of MG132 and NEM on ISG15
conjugates suggested that an additional step(s) was involved. Expression of α-actin was not altered by NEM or MG132 treatment, and served as a control for protein quantitation ( figure   6C ). The results from these experiments were quantified by densitometry and are depicted in figure 6 , panels D and E. Taken together, these data support a model in which the increase in ISG15 conjugates by MG132 requires de novo ISG15 conjugation, and is independent of ISG15 deconjugating activity.
The ISG15 E1 enzyme, UBE1L, is not regulated by the proteasome.
De novo ISG15 conjugation is required for the proteasome inhibitor-mediated increase in hours prior to harvesting cell lysates. Western blot analysis revealed a strong induction of UBE1L by IFN; however, the protein level was not increased following MG132 treatment (figure 7B). Expression of α-actin served as a control for protein quantitation in these blots ( figure 7A and B, lower panel). These findings indicate that stabilization of UBE1L is not the mechanism by which proteasome inhibitors stimulate ISG15 conjugation.
Modification of ISG15 substrates by ub.
In the absence of de novo conjugation, ISG15 conjugates do not accumulate in MG132 conjugates increased in proteasome inhibitor treated cells, suggesting that co-modification is not the primary mechanism by which proteasome inhibition leads to an increase in ISG15
conjugates. Indeed smaller molecular mass ISG15 conjugate species that were markedly increased in response to proteasome inhibitor (figure 1) did not appear as potentially co-modified proteins. The identification of specific ISG15/ub immunoreactive species is required to definitively address co-modification by ISG15 and ub.
DISCUSSION
The ubiquitin-proteasome pathway accounts for 80-90% of protein turnover in cells, and affects nearly every cellular process (4). Ubls are a growing class of posttranslational modifier that are conjugated to target proteins through an analogous enzymatic pathway to that of ub.
Recent studies have determined that ub and ubl conjugation pathways can intersect through common substrates (7), and reciprocal regulation (8, 9) . ISG15 is an IFN-induced ubl; however, a relationship between ISG15 conjugation and proteasome function has not been investigated.
Therefore, we examined the effect of proteasome inhibitors on the population of ISG15 ATP depletion is not predicted to alter DUB activity, yet it abrogated the MG132-dependent increase in ISG15 conjugates; therefore, the modulation of UBP43 activity did not appear to be a primary mechanism by which proteasome inhibitors stimulate ISG15 conjugates. However, a striking increase in ISG15 conjugates was observed in cells from UBP43-/-mice, which mimicked the effect of proteasome inhibitor treatment (22) . This finding indicated that the ISG15 conjugate pool is dynamically regulated and demonstrated the role of UBP43 in this process.
Therefore, we employed the thiol-alkylating agent, NEM, to investigate a potential contribution of UBP43 to the MG132-dependent increase in ISG15 conjugates. NEM treatment, which inhibits ub and ubl conjugating and deconjugating enzymes, resulted in a dose-dependent stimulation of ub and ISG15 conjugates, reflecting the inhibition of ub and ISG15 deconjugating activity by NEM. However, NEM antagonized MG132-dependent increase of ISG15 conjugates, but not the increase of ub conjugates. The opposing effects of NEM and MG132 on ISG15 conjugation suggested that these agents stimulate ISG15 conjugates by distinct mechanisms.
The inhibition of ub-DUB activity by NEM may result in the accumulation of poly-ub chains This quantitative and selective change in ISG15 conjugates suggests that authentic ISG15
conjugates are directly or indirectly proteasome regulated, and that the proteasome inhibitordependent increase in ISG15 conjugates is biologically relevant, and not due to conjugation to non-substrate proteins stabilized by MG132.
In addition to modulating protein stability by antagonizing ub conjugation, an established function of ubls involves targeting their conjugates to specific subcellular compartments. For example, the first SUMO conjugate identified, RanGAP1, requires SUMO modification for its localization to the nuclear pore (46, 47) . More recently, SUMO modification was determined to be critical for targeting proteins for subnuclear structures known as nuclear bodies (48) .
Similarly, immunofluorescence staining revealed that a subpopulation of free ISG15 and its conjugates are associated with the intermediate filament network (23) . Employing differential detergent fractionation, we confirmed this localization, and determined that a significant fraction of free ISG15, but only a very small fraction of conjugates is loosely associated with the cytoskeleton. Strikingly, a substantial portion of the MG132-stimulated ISG15 conjugates was resistant to detergent extraction, and thus cofractionated with cytoskeletal proteins. MG132 treatment reduced the level of free ISG15 loosely associated with the cytoskeleton, suggesting that free ISG15 is conjugated to cytoskeletal components or tightly associated proteins upon The cytoskeleton functions to provide mechanical strength, maintain cell shape, and regulate vesicle trafficking and cell movement (50) through the cooperative interaction of microfilaments, microtubules, and intermediate filaments (51) . The cytoskeleton is also important for viral trafficking and replication (52, 53) . For both herpes simplex virus 1 (HSX1) and adenovirus serotype 2, transport from the cell periphery to the nucleus after host entry is dependent on the interaction of specific viral proteins with the microtubule network (54, 55) . Accordingly, disruption of microtubules results in a 40% reduction in HSX1 nucleocapsid transport to the nucleus (56) . In the export of assembled viral progeny, vaccinia viral capsids sequentially interact with microtubule and actin networks to translocate from the site of replication (57) . For viruses that assemble at the plasma membrane including influenza and retroviruses, viral proteins have also been found to be associated with cytoskeleton (58, 59 
